Adalvo’s Firazyr Generic on Track to Becoming Available in EU

Adalvo’s Firazyr Generic on Track to Becoming Available in EU

309546

Adalvo’s Firazyr Generic on Track to Becoming Available in EU

Adalvo has completed a mandatory requirement for a marketing authorization in the European Union for its generic version of Firazyr (icatibant injection), which is approved for acute attacks in adults with hereditary angioedema (HAE), the company has announced. The successful closure of the decentralized procedure came more than a year after Adalvo submitted applications to the European Medicines Agency seeking approval to commercialize its icatibant pre-filled syringe. The decentralized procedure is used by companies seeking…

You must be logged in to read/download the full post.